Anti-EGFR-Based Therapy in Recurrent or Metastatic HNSCC – What Difference Does it Make?

Autor:	Hendrik Eggers, Lea Häbel, Arnold Ganser, Viktor Grünwald, Roland Merten, Athanasia Warnecke, Martin Durisin, Philipp Ivanyi
Rok vydání:	2022
Předmět:	Cancer Research Oncology Medizin General Medicine
Zdroj:	Cancer Investigation. 41:93-100
ISSN:	1532-4192 0735-7907
Popis:	Patients with R/M HNSCC treated with palliative first-line therapy at Hannover Medical School between October 2005 and December 2016 have been included to show changes in survival following broad utilization of cetuximab. Treatment periods were defined from 10/2005 to 12/2008 (Period A) and 01/2009 to 12/2016. Overall survival did not improve over time. However, in subgroup analysis cetuximab utilized at any time vs. never showed a significant improve of overall survival (11.3 vs. 6.3 months, HR: 0.55, 95%-CI: 0.4-0.8
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5da0143c8c89bee313282fbce9cd64c5 https://doi.org/10.1080/07357907.2022.2134414 Zobrazit plný text záznamu